We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




HTS Method Based on 3D Tumor Organoid Cultures

By LabMedica International staff writers
Posted on 30 Apr 2018
A drug development team has described a high-throughput screening (HTS)-compatible method – based on three-dimensional (3D) tumor organoids – for evaluating multiple chemical compounds for potential chemotherapeutic drug candidates.

Traditional high-throughput drug screening in cancer research routinely relies on two-dimensional cell models, which inadequately recapitulate the physiologic context of cancer. More...
Three-dimensional cell models are thought to better mimic the complexity of in vivo tumors. Numerous methods to culture three-dimensional organoids have been described, but most are nonhomogeneous and expensive, and hence impractical for high-throughput screening (HTS) purposes.

Investigators at the Scripps Research Institute (Jupiter, FL, USA) sought to develop an improved screening method based on three-dimensional organoids. To this end, the described in the April 19, 2018, online edition of the journal SLAS Discovery an HTS-compatible method that enabled the consistent production of organoids in standard flat-bottom 384- and 1536-well plates by combining the use of a cell-repellent surface with a bio-printing technology incorporating magnetic force.

This novel method combined specialized high-density microtiter plates formulated with an ultra-low attachment surface along with gold nanoparticles (nanoshuttles), which were used to label cancer cells in vitro. Once labeled, a magnet assembled the cells into a three-dimensional spheroid or organoid structure. This three-dimensional structure was retained, and chemical compounds were added to assess their therapeutic efficacy.

The investigators validated this process by evaluating the effects of well-characterized anticancer agents against four patient-derived pancreatic cancer KRAS mutant-associated primary cells, including cancer-associated fibroblasts. The technology was tested for its compatibility with HTS automation by completing a cytotoxicity pilot screen of around 3300 approved drugs.

Data obtained during the study indicated that the technique could be readily applied to support large-scale drug screening relying on clinically relevant, three-dimensional tumor models directly harvested from patients, an important milestone toward personalized medicine.

Related Links:
Scripps Research Institute


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Collection and Transport System
PurSafe Plus®
Laboratory Software
ArtelWare
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The TriVerity IVD test includes the TriVerity cartridge and the Myrna instrument (Photo courtesy of Inflammatix)

Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients

When a patient enters the emergency department in critical condition, clinicians must rapidly decide whether the patient has an infection, whether it is bacterial or viral, and whether immediate treatment... Read more

Technology

view channel
Image: The technology could be used for the early diagnosis of diseases such as cancers and Alzheimer\'s (Photo courtesy of PolyU)

3D Micro-Printed Sensors to Advance On-Chip Biosensing for Early Disease Detection

Early-stage disease diagnosis depends on the ability to detect biomarkers with exceptional sensitivity and precision. However, traditional biosensing technologies struggle with achieving this at the micro-scale,... Read more

Industry

view channel
Image: ELITechGroup’s unique Real-Time PCR technologies include the revolutionary Minor Groove Binder (Photo courtesy of ELITechGroup)

ELITech and Hitachi High-Tech to Develop Automated PCR Testing System for Infectious Diseases

Molecular testing has become central to diagnosing and monitoring infectious diseases by analyzing genetic information. The use of PCR during the COVID-19 pandemic showed its value, but traditional systems... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.